ABT

Abbott Laboratories
D

ABT

Arincen83/100B
115.550
USD
6.14
(5.61%)
Post Trading·115.230USD-0.320(-0.28%)
Last updated: · Delayed 15 min
Fair valueNot reliable
Q4 FY2026 · Earnings report
EPS estimate 1.64Revenue estimate 13.22B
OverviewFinancialsSignalsNewsForecastEarningsDividendsCompany

Abbott Laboratories stock buybacks 1989–2026

Abbott Laboratories spent 1.05B USD buying back its shares in Q2 FY2026, the three months to 30 June 2026, up 17,316.7% on the same quarter a year before. Abbott Laboratories spent 1.83B USD buying back its shares over the last twelve months, up 35.5% on the twelve months before. In fiscal year 2025 it spent 893.00M USD, down 31.0% on the year before.

Last updated 3 Nov 2026 · Next report 28 Jan 2027

Stock buybacks

Growth

Fiscal yearPeriod endingStock buybacksGrowthDividends paidFree cash flow
TTM30 Jun 20261.83B+35.50%4.26B8.72B
FY202531 Dec 2025893.00M-31.04%4.12B7.40B
FY202431 Dec 20241.30B+5.54%3.84B6.35B
FY202331 Dec 20231.23B-67.67%3.56B5.06B
FY202231 Dec 20223.80B+65.07%3.31B7.80B
FY202131 Dec 20212.30B+470.47%3.20B8.65B
FY202031 Dec 2020403.00M-43.87%2.56B5.72B
FY201931 Dec 2019718.00M+201.68%2.27B4.50B
FY201831 Dec 2018238.00M-71.22%1.97B4.91B
FY201731 Dec 2017827.00M+58.43%1.85B4.44B
FY201631 Dec 2016522.00M-76.67%1.54B2.08B
FY201531 Dec 20152.24B+1.91%1.44B1.86B
FY201431 Dec 20142.20B+36.76%1.34B2.60B
FY201331 Dec 20131.61B-32.11%882.00M2.18B
FY201231 Dec 20122.36B+2,969.85%3.18B7.52B
FY201131 Dec 201177.01M-91.12%2.94B7.48B
FY201031 Dec 2010866.83M+4.90%2.67B7.72B
FY200931 Dec 2009826.35M-23.61%2.41B6.19B
FY200831 Dec 20081.08B+2.17%2.17B6.06B
FY200731 Dec 20071.06B+40.33%1.96B3.53B
FY200631 Dec 2006754.50M-42.06%1.78B3.99B
FY200531 Dec 20051.30B+160.60%1.69B3.97B
FY200431 Dec 2004499.75M+411.94%1.60B3.12B
FY200331 Dec 200397.62M—1.21B2.50B
FY200231 Dec 20020.00-100.00%1.43B2.89B
FY200131 Dec 200117.36M-96.26%1.27B2.40B
FY200031 Dec 2000464.86M—1.15B2.06B
FY199931 Dec 19990.00-100.00%1.00B1.95B
FY199831 Dec 1998876.30M-16.90%891.70M1.49B
FY199731 Dec 19971.05B+30.38%809.60M1.42B
FY199631 Dec 1996808.80M+4.85%728.10M1.43B
FY199531 Dec 1995771.41M+25.24%653.57M1.97B
FY199431 Dec 1994615.95M+32.23%602.36M2.21B
FY199331 Dec 1993465.82M-23.33%548.04M1.85B
FY199231 Dec 1992607.60M+91.19%488.40M381.60M
FY199131 Dec 1991317.80M-47.52%410.30M682.60M
FY199031 Dec 1990605.60M+109.19%351.20M559.50M
FY198931 Dec 1989289.50M—301.90M386.80M

Figures in USD. Free cash flow is operating cash flow less capital expenditure. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

The money spent buying back the company's own shares in each period, from the cash flow statement.

See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Cash flow

Common questions about Abbott Laboratories's buybacks

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.